The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

FDA warns kratom sellers to stop making unproven claims about chronic pain, opioid addiction benefits

| | July 8, 2019

The Food and Drug Administration is still pressing down hard on kratom—the plant treatment that adherents say has helped them manage their opioid addiction or chronic pain. [June 25] the agency announced it was sending warning letters to two online marketers and distributors, accusing them of illegally selling kratom products with false or unproven claims about their health benefits.

These claims, detailed by the FDA in its warning letters to the two firms, include that kratom can help with opioid addiction or pain relief, but also go as far as to suggest that it can treat arthritis, insomnia, and even cancer.

“Despite our warnings, companies continue to sell this dangerous product and make deceptive medical claims that are not backed by science or any reliable scientific evidence,” Ned Sharpless, the current acting FDA chief, said in a statement. “As we work to combat the opioid crisis, we cannot allow unscrupulous vendors to take advantage of consumers by selling products with unsubstantiated claims that they can treat opioid addiction or alleviate other medical conditions.”

Read full, original post: FDA Is Going After Kratom, Warning Companies to Stop Selling It for Opioid Addiction and Cancer

Related article:  An hour of exercise a week might be enough to stave off brain shrinkage, study shows
The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend